Examkin

Question

Difficulty: Very hardPreventive Care and Immunizations

A 2-month-old girl is brought to the clinic for her first well-child examination. She was born at 39 weeks gestation via spontaneous vaginal delivery. Her mother has a history of severe, refractory Crohn's disease, which has been managed with regular infusions of infliximab throughout the pregnancy, with the final dose administered at 36 weeks gestation. The infant's newborn screen was normal. She has been exclusively breastfed and is gaining weight well. On examination, the infant appears well. She smiles responsively, makes cooing sounds, and tracks the examiner's face past the midline. When placed in the prone position, she is able to lift her head to 45 degrees. The mother expresses concern that the infant is not yet reaching for objects or rolling over. Her tone and reflexes are normal. She previously received the Hepatitis B vaccine at birth. Which of the following is the most appropriate next step in management regarding her immunizations and development?

  1. Reassure the mother regarding development; administer DTaP, Hib, PCV, IPV, and Hepatitis B vaccines; and withhold the rotavirus vaccineAnswer
  2. B
    Reassure the mother regarding development; administer DTaP, Hib, PCV, IPV, Hepatitis B, and rotavirus vaccines
  3. C
    Refer for developmental evaluation; administer DTaP, Hib, PCV, IPV, and Hepatitis B vaccines; and withhold the rotavirus vaccine
  4. D
    Refer for developmental evaluation; administer DTaP, Hib, PCV, IPV, Hepatitis B, and rotavirus vaccines
  5. E
    Reassure the mother regarding development; and withhold all immunizations until 6 months of age

Answer

The most appropriate management is to reassure the mother regarding the infant's normal development, administer all routine inactivated vaccines (DTaP, Hib, PCV, IPV, Hepatitis B), and withhold the live rotavirus vaccine.
The correct management is to reassure the mother regarding the infant's normal development, administer the routine inactivated vaccines, and withhold the live rotavirus vaccine. At 2 months of age, normal milestones include social smiling, cooing, tracking past the midline, and lifting the head to 45 degrees when prone. The mother's concerns regarding the lack of reaching for objects and rolling over are unfounded, as these are typically 4-month milestones; therefore, reassurance is appropriate rather than a developmental referral. Regarding immunizations, the routine 2-month schedule includes DTaP, Hib, PCV, IPV, Hepatitis B, and rotavirus. However, this infant was exposed to infliximab (a TNF-alpha inhibitor) in utero during the third trimester. Monoclonal IgG antibodies actively cross the placenta and can cause profound immunosuppression in the infant for up to 6 months after birth. Consequently, the administration of live-attenuated vaccines, such as the oral rotavirus vaccine, is strictly contraindicated during this period due to the risk of severe, disseminated vaccine-strain infection. In contrast, all inactivated vaccines are safe and should be administered according to the normal schedule.

Step-by-Step Solution

1
Assess the infant's developmental milestones.
The infant smiles, coos, tracks past the midline, and lifts her head 45 degrees when prone. The lack of reaching and rolling over is entirely normal at 2 months of age.
To address the mother's concerns and determine if a developmental referral is clinically warranted.
2
Determine the routine immunization requirements at 2 months of age.
The standard schedule includes DTaP, Hib, PCV, IPV, Hepatitis B, and rotavirus vaccines.
To establish the baseline recommended vaccines before considering maternal and patient history for contraindications.
3
Identify any contraindications based on the infant's in utero exposure.
The infant was exposed to infliximab (an IgG1 monoclonal antibody) in utero. These biologic agents actively cross the placenta and cause systemic immunosuppression in the infant that can persist for up to 6 months.
Maternal use of biologic immunosuppressants dictates the safety profile of live vaccines in the neonate.
4
Synthesize the findings to formulate the safest management plan.
Reassure the mother about development. Administer all inactivated vaccines, as they are safe. Withhold the live rotavirus vaccine to prevent disseminated vaccine-strain infection.
To provide necessary preventive care while avoiding life-threatening complications in an immunocompromised host.

Key Concept

Infants exposed to biological immunomodulators (e.g., infliximab, adalimumab) in utero during the second or third trimester should not receive live-attenuated vaccines (like rotavirus) for the first 6 months of life, though all inactivated vaccines should be administered on the standard schedule.
Rate this question

Topics

Preventive Care and Immunizations

More questions from this topic